Charcot-Leyden crystals: pathology and diagnostic utility.
Eosinophilia is associated with several diseases of the upper respiratory tract. The predominance of eosinophils in nasal tissue, secretions, and lavage fluid has been used as an aid in the diagnosis of allergic rhinitis. Charcot-Leyden crystals, considered to be a morphologic hallmark of eosinophil-related disease, are often also found in inflamed nasal tissue and paranasal sinus contents of patients with allergic rhinitis. These bipyramidal-shaped crystals are composed of the enzyme lysolecithin acylhydrolase, one of several eosinophilic proteins that damage respiratory epithelium and contribute to the pathology of allergy in the upper respiratory tract.
Several diseases of the upper respiratory tract are associated with increased numbers of eosinophilic leukocytes, with or without blood eosinophilia, in the nasal mucosa and its secretions. (1-2) In patients with nasal polyps, marked infiltration of the polypoid tissue with activated eosinophils is a common finding. (3) Nasal challenge with antigen usually results in an eosinophil-rich infiltrate of inflammatory ceils into the paranasal sinuses, (4) as early as 30 minutes after exposure. (5)
Charcot-Leyden crystals (CLCs) are accepted as a morphologic hallmark of eosinophil-related disease in which there is active eosinophilic inflammation or proliferation. (4,6) Therefore, it is not surprising to find these distinctive bipyramidal-shaped crystals within inflamed nasal tissue and paranasal sinus contents in patients with allergic rhinitis (figure 1). CLC formation and the presence of these crystals within tissue and secretions of the upper respiratory tract, however, represent more than just an intriguing crystalline artifact. As discussed in this article, these crystals contain biologically active substances that contribute to the pathology of allergy in the upper respiratory tract.
[FIGURE 1 OMITTED]
CLCs were first described more than a century ago. (7,8) They have since been observed in many human tissues, neoplasms, body secretions, and fecal material. (9,10) CLC protein has been localized to crystalloid-free granules within eosinophils. (11,12) Cytoplasmic granules that are found in mature human eosinophils consist of 4 categories (13): (1) large crystalloid-containing secondary granules, (2) large and medium-sized crystalloid-free primary granules, (3) small granules, and (4) microgranules. Once the eosinophil has migrated into tissue, it becomes active and releases inflammatory mediators from these granules. These include major basic protein, eosinophilic cationic protein, eosinophil peroxidase, platelet-activating factor, and CLC protein. (14) When released, CLC protein aggregates to form distinctive crystals.
CLCs are composed of the single CLC protein called lysolecithin acylhydrolase, which has lysophospholipase activity. (15,16) This protein comprises approximately 10% of the total cellular protein in eosinophils. Its true biologic function is not known. However, lysolecithin acylhydrolase is one of several eosinophil proteins with cytotoxic properties involved in the eosinophil's antiparasitic, antineoplastic, and immune functions. This enzyme also has been shown to damage the respiratory epithelium and increase vascular permeability. (17,18) Even after the disintegration of eosinophils, CLCs may retain their enzyme activity and continue to degrade lysophospholipids. (15)
The predominance of eosinophils in nasal tissue, secretions, and lavage fluid has been used as an easy, sensitive, and specific aid in the diagnosis of allergic rhinitis. (19,20) CLCs, as alluded to before, are a morphologic hallmark of eosinophil-related disease. Eosinophils are almost always present near the crystals. (21) The fragile crystals are evident via light microscopy as eosinophilic compass-needle-like structures. They stain pink to red with hematoxylin-eosin and black with iron-hematoxylin stains. (22) They also stain with Giemsa (figure 2) and Mallory's phosphotungstic acid stain. The crystals are birefringent with polarized light (figure 3) and are readily detected with an epifluorescent microscope. (23) Their presence in specimens from the upper respiratory tract should always lead to a careful search for associated fungal hyphae and spores. (24,25) It is extremely important to recognize allergic fungal sinusitis and to be able to differentiate it from other forms of sinusitis, because the treatments and prognoses for these disorders differ significantly. (25)
[FIGURES 2-3 OMITTED]
(1.) Stoop AE, van der Heijden HA, Biewenga J, van der Bean S. Eosinophils in nasal polyps and nasal mucosa: An immunohistochemical study. J Allergy Clin Immunol 1993;91:616-22.
(2.) Vaheri E. Nasal allergy with special reference to eosinophilia and histopathology. Acta Allergol 1956; 10:203-11.
(3.) Stoop AE, van der Heijden HA, Biewenga J, van der Bean S. Lymphocytes and nonlymphoid cells in human nasal polyps. J Allergy Clin Immunol 1991;87:470-5.
(4.) Weller PF. The immunobiology of eosinophils. New Engl J Med 1991;324:1110-18.
(5.) Feather IH, Wilson SJ. Eosinophils in rhinitis. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Boston: Blackwell Scientific Publications, 1995:347-63.
(6.) Leonidas DD, Elbert BL, Zhou Z, et al. Crystal structure of human Charcot-Leyden crystal protein, an eosinophil lysophospholipase, identifies it as a new member of the carbohydrate-binding family of galectins. Structure 1995;3:1379-93.
(7.) Charcot JM, Robin C. Observation de leucocythemie. Mem Soc Biol (Paris) 1853;5:44-50.
(8.) Leyden E. Zur Kenntriss des Asthma bronchiale. Virchows Arch A 1872;54:324-44.
(9.) Archer GT, Blackwood A. Formation of Charcot-Leyden crystals in human eosinophils and basophils and study of the composition of isolated crystals. J Exp Med 1965; 122:173-80.
(10.) Carson HJ, Buschmann RJ, Weisz-Carrington P, Choi YS. Identification of Charcot-Leyden crystals by electron microscopy. Ultrastruct Pathol 1992; 16:403-11.
(11.) Welsh RA. The genesis of the Charter-Leyden crystal in the eosinophilic leukocyte of man. Am J Pathol 1959;35:1091-7.
(12.) Dvorak AM, Letourneau L, Login GR, et al. Ultrastructural localization of the Cheroot-Leyden crystal protein (lysophospholipase) to a distinct crystalloid-free granule population in mature human eosinophils. Blood 1988;72:150-8.
(13.) Weller PF, Dvorak AM. Human ensinophils: Development, maturation, and functional morphology. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Boston: Blackwell Scientific Publications, 1995:255-74.
(14.) Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol2000; 105:651-63.
(15.) Weller PF, Goetzl EJ, Austen KF. Identification of human eosinophil lysophospholipase as the constituent of Cheroot-Leyden crystals. Proc Natl Acad Sci 1980;77:7440-3.
(16.) Weller PF, Bach D, Austen KF. Human eosinophil lysophospholipase: The sole protein component of Charcot-Leyden crystals. J Immunol 1982;128:1346-9.
(17.) Harlin SL, Ansel DG, Lane SR, et el. A clinical and pathologic study of chronic sinusitis: The role of the eosinophil. J Allergy Clin Immunol 1988;81:867-75.
(18.) Jordana M, Dolovich J, Ohno I, et al. Nasal polyposis: A model for chronic inflammation. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Boston: Blackwell Scientific Publications, 1995; 156-64.
(19.) Kaufman HS Rosen I, Shaposhnikov N, Wai M. Nasal eosinophilia" Ann Allergy 1982;49:270-1.
(20.) Miller RE, Paradise JL, Friday GA, et el. The nasal smear for eosinophils. Its value in children with seasonal allergic rhinitis. Am J Dis Child 1982;136:1009-11.
(21.) Arora VK, Singh N, Bhatia A. Charcot-Leyden crystals in fine needle aspiration cytology. Acta Cytol 1997;41:409-12.
(22.) Ayres WW, Starkey NM. Studies on Charcot-Leyden crystals. Blood 1950:254-66.
(23.) Lo JW, Fung CH. Autofluorescent Charcot-Leyden crystals. Arch Pathol Lab Med 1992; 116:1101.
(24.) Jonathan D, Lund V, Milroy C. Allergic aspergillus sinusitis--An overlooked diagnosis? J Laryngol Otol 1989; 103:1181-3.
(25.) Bent JP III, Kuhn FA. Diagnosis of allergic fungal sinusitis. Otolaryngol Head Neck Surg 1994;111:580-8.
From the Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston.
Reprint requests: Liron Pantanowitz, MD, Department of Pathology, Beth Israel Deaconess Medical Center, 300 Brookline Ave., Boston, MA 02215. Phone: (617) 667-4344; fax: (617) 667-7120; e-mail: firstname.lastname@example.org
|Printer friendly Cite/link Email Feedback|
|Publication:||Ear, Nose and Throat Journal|
|Date:||Jul 1, 2004|
|Previous Article:||A case of recurrent subcutaneous emphysema as a complication of endotracheal intubation.|
|Next Article:||Parathyroid carcinoma: a multicenter review of clinicopathologic features and treatment outcomes.|
|EXONHIT INITIATES PHASE II CLINICAL TRIAL FOR EHT 0201.|
|Probing Pictures: Carol Armstrong on Georges Didi-Huberman.|
|Fluconazole nasal spray in the treatment of allergic fungal sinusitis: a pilot study.|